BIIB34:BVMF
Biogen
230,10 BRL
0,00%
(0,00) 1 d.
4. 11., 15:38:07 GMT-3 · BRL
search
Všetky symboly
| Symbol | Cena | Zmena | % zmeny |
|---|
insights_autoGenerujú sa najdôležitejšie štatistiky pre BIIB34…
Trh. kap.
36,92 mld.
Priem. obj.
9,00
Objem
0,00
Max. za 52 týž.
230,10 BRL
Min. za 52 týž.
147,50 BRL
Akcie v obehu
147,82 mil.
Počet zamestnancov
8 tis.
Trh. kap.
36,92 mld.
Priem. obj.
9,00
Objem
0,00
Max. za 52 týž.
230,10 BRL
Min. za 52 týž.
147,50 BRL
Akcie v obehu
147,82 mil.
Počet zamestnancov
8 tis.
Spravodajstvo
Z internetových zdrojov a od spravodajských partnerov
Investing.com
·
pred 2 hodinami
Needham reiterates Biogen stock rating on Alzheimer’s drug data
Yahoo Finance
·
pred 2 hodinami
Biogen (BIIB) After Fresh Alzheimer’s Data, Is The Valuation Story Still Compelling?
Yahoo Finance
·
pred 16 hodinami
Biogen Prepares Joint Lupus Trial Results as It Targets First Revenue Growth Since 2019
Yahoo Finance
·
pred 17 hodinami
Biogen: 3 Key Takeaways for Long-Term Investors
Profil
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
Informácie o subjekte Biogen
Generálny riaditeľChris Viehbacher
Zamestnanci7,5 tis.
Dátum založenia1978
Hlavné sídloCambridge, Massachusetts, Spojené štáty americké
OdvetvieHealth Care
Odvetvie-
Webbiogen.com